Kikuchi Masahiro, Koyasu Sho, Shinohara Shogo, Usami Yu, Imai Yukihiro, Hino Megumu, Itoh Kyo, Tona Risa, Kanazawa Yuji, Kishimoto Ippei, Harada Hiroyuki, Naito Yasushi
Department of Otolaryngology-Head and Neck Surgery, Kobe City Medical Center General Hospital, Kobe City, Japan.
Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kobe City, Japan.
Head Neck. 2015 Oct;37(10):1524-31. doi: 10.1002/hed.23784. Epub 2014 Jul 21.
The purpose of this study was to determine whether pretreatment 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG PET/CT) volume-based parameters, such as metabolic tumor volume and total lesion glycolysis, add more prognostic information in patients with oropharyngeal squamous cell carcinoma (SCC).
The subjects were 47 patients with oropharyngeal SCC who underwent 18F-FDG PET/CT before any treatment and followed by definitive therapy. PET parameters (metabolic tumor volume and total lesion glycolysis) and tumor p16/p53 status were evaluated retrospectively. Univariate and multivariate analyses were performed for disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS).
All volume-based PET parameters were found to be significant prognostic factors for DFS, DSS, and OS in univariate analysis. In multivariate analysis, only metabolic tumor volume for total tumor lesions (cutoff 65) retained an independent association with DFS, DSS, and OS.
Metabolic tumor volume for total tumor lesions may be a predictive marker for survival outcomes in patients with oropharyngeal SCC with known p16/p53 status.
本研究的目的是确定治疗前基于18F-氟脱氧葡萄糖-正电子发射断层扫描(18F-FDG PET/CT)体积的参数,如代谢肿瘤体积和总病变糖酵解,是否能为口咽鳞状细胞癌(SCC)患者提供更多预后信息。
研究对象为47例口咽SCC患者,这些患者在接受任何治疗前均接受了18F-FDG PET/CT检查,随后接受了确定性治疗。回顾性评估PET参数(代谢肿瘤体积和总病变糖酵解)以及肿瘤p16/p53状态。对无病生存期(DFS)、疾病特异性生存期(DSS)和总生存期(OS)进行单因素和多因素分析。
在单因素分析中,所有基于体积的PET参数均被发现是DFS、DSS和OS的显著预后因素。在多因素分析中,仅总肿瘤病变的代谢肿瘤体积(临界值65)与DFS、DSS和OS保持独立关联。
对于已知p16/p53状态的口咽SCC患者,总肿瘤病变的代谢肿瘤体积可能是生存结局的预测标志物。